A refreshed chronic kidney disease formulary will provide clear prescribing guidance across SystmOne. It will include separate protocols for ACE inhibitors and ARBs, plus guidance for SGLT2 inhibitors and finerenone, with relevant dosing and patient eligibility information. The formulary will also include clear links and guidance for using CKD test results. EMIS coming soon.